Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study

BACKGROUND: Pemetrexed and bevacizumab as monotherapies, or in combination, have been approved for maintenance therapy following platinum‐based induction in patients with advanced nonsquamous non‐small cell lung cancer (NSCLC). The differences in the benefits of bevacizumab for treatment during earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jun, Ni, Hanping, Wang, Xiaoyan, Si, Yan, Xu, Mengzhao, Wang, Xiaotong, Zhang, Li, Zhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327679/
https://www.ncbi.nlm.nih.gov/pubmed/32406994
http://dx.doi.org/10.1111/1759-7714.13469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327679/
https://www.ncbi.nlm.nih.gov/pubmed/32406994
http://dx.doi.org/10.1111/1759-7714.13469

Ejemplares similares